A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)

Trial Profile

A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Daratumumab; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 19 Jul 2016 Daratumumab, Pomalidomide drugs are added into the treatment hence treatment arms has been changed from 4 to 10. New primary endpoints added instead of the previous end points and patient numbers also increases.
    • 19 Jul 2016 Planned number of patients changed from 46 to 214.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top